| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,||
* Department of Men's Healthcare, Bayer-Schering,
Berlin, Germany; the Gulf Medical College
School of Medicine, Ajman, United Arab Emirates;
VU University Medical Center, Amsterdam, The
Netherlands; Urology Office, Bremerhaven,
Germany; and the || Department of Urology,
Segeberger Kliniken, Norderstedt, Germany
| Correspondence to: Dr Farid Saad, Bayer-Schering, Department of Men's Healthcare, 13342 Berlin, Germany (e-mail: farid.saad{at}bayerhealthcare.com). |
| Received for publication February 28, 2007; accepted for publication September 13, 2007. |
 |
Abstract |
|---|
 Top Abstract Patients and MethodsResultsDiscussionReferences |
|---|
Key words: International index of erectile function, waist circumference, lipids, sex hormone–binding globulin, prostate safety, hematocrit.
The criteria for efficacious androgen treatment require that plasma T levels are in the normal range for the full 24 hours of the day during the interval between 2 administrations (World Health Organization, 1992). The normal range of plasma T levels in eugonadal men is very wide—between 3.0 and 8.6 ng/mL or 10 to 35 nmol/L in most laboratories. It is becoming increasingly clear that the thresholds for androgen actions vary for the various androgen-dependent biologic functions and that these thresholds differ among men (Kelleher et al, 2004; Zitzmann et al, 2006).
In this study, we analyzed the impact of 2 androgen treatment modalities, T gel and long-term parenteral T undecanoate (TU), in androgen-deficient men with "late-onset hypogonadism." The value of these 2 treatment modalities of T has been well documented (Wang et al, 2004; Harle et al, 2005; Nieschlag, 2006). These 2 treatment modalities, although meeting the requirement to restore plasma T levels to within reference values, generate different patterns and magnitudes of changes in plasma T levels (World Health Organization, 1992; Nieschlag, 2006).
The men participating in this study complained of sexual dysfunction. There is increasing evidence that sexual dysfunction in elderly men is associated with the metabolic syndrome (Bansal et al, 2005; Grover et al, 2006; Jackson, 2006; Kupelian et al, 2006b) of which the key elements are visceral obesity, hypertension, insulin resistance and dyslipidemia (Grundy et al, 2004; Ford, 2005). The metabolic syndrome, in turn, is associated with lower than normal plasma T levels (Ford, 2005; Kalme et al, 2005; Kupelian et al, 2006a), and low plasma T levels predict the metabolic syndrome (Laaksonen et al, 2004; Kupelian et al, 2006a). Therefore, the impact that these 2 treatment regimens had on sexual dysfunction, symptoms of the metabolic syndrome, and parameters of safety of T administration were analyzed.
|
Patients and Methods |
|---|
|
TopAbstractPatients and MethodsResultsDiscussionReferences |
|---|
This prospective study analyzed the dose-response effects of 2 treatment modalities of T: T gel (Testogel; Bayer Schering, Berlin, Germany) and TU (Nebido; Bayer Schering, Berlin, Germany). Pharmacokinetic profiles of these 2 modalities have been extensively studied. T gel was a daily application (Wang et al, 2004), and the first 2 injections of 1000 mg each of TU (Schubert et al, 2004; Nieschlag, 2006) were administered with an interval of 6 weeks (loading dose) followed by injections every 12 weeks. The total observation period was 9 months for each treatment modality.
Two cohorts of elderly men with late-onset hypogonadism were studied. Group 1 (n = 28; mean age, 61 years; mean T level, 2.07 ± 0.05 ng/mL) was treated for 9 months with long-acting TU (1000 mg at weeks 0 and 6 and thereafter every 12 weeks). Group 2 (n = 27; mean age, 60 years; mean T level, 2.24 ± 0.41 ng/mL) was treated with T gel (50 mg/day). Throughout this observation period, there were no dose adaptations. Many of these patients were suffering from the metabolic syndrome, cardiovascular disease, and/or type 2 diabetes mellitus, for which most received drug treatment. There were no statistically significant differences in baseline variables between the 2 groups except that weight was higher in the group receiving T gel.
Whether patients received treatment with T gel or TU was their own
preference. Patients were examined every 3 months. The follow-up period was 9
months. At baseline and every 3 months, the following variables were assessed
(for treatment with TU, measurements were taken before the next injection was
due): plasma T levels, sex hormone–binding globulin (SHBG),
international index of erectile function (IIEF) score, aging male scale (AMS)
score, waist circumference (which is now viewed as a pivotal index of the
metabolic syndrome), systolic/diastolic blood pressure, and levels of plasma
total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein
(HDL), and triglycerides. The following safety parameters were assessed:
plasma PSA, international prostate symptoms score (IPSS), blood glucose
levels, hemoglobin A1c levels, hemoglobin and hematocrit levels, and tests of
liver functions (levels of serum bilirubin, 
-glutamyl transpeptidase
[GT], serum glutamic oxaloacetic transaminase [SGOT], and serum
glutamic pyruvic transaminase [SGPT]).
Plasma T levels were measured with immunoassays (Architect intra-assay; Abbott Diagnostics, Abbott Park, Ill); variation was 3.4% and interassay variation was 5.1%. Plasma SHBG levels were measured with Immulite 2000 chemiluminescence immunochemical assay (Siemens Medical Solutions Diagnostics, Tarrytown, NY); intra-assay variation was 2.5% and interassay variation 4.2%.
Statistical Analysis
Data were analyzed by descriptive statistical methods using SAS version
6.12 (SAS Institute Inc, Cary, NC). The Wilcoxon rank sum test was used to
compare the 2 groups at baseline. Treatment-induced changes in the parameters
of interest were analyzed for each group using the Wilcoxon signed rank test.
All results are presented as means ± SD. Changes in waist circumference
were correlated to changes in plasma total cholesterol, LDL, HDL, and
triglycerides with Pearson's correlation test.
|
Results |
|---|
|
TopAbstractPatients and MethodsResultsDiscussionReferences |
|---|
Plasma T levels in both cohorts were measured every 3 months and showed values significantly above baseline levels. However, during treatment plasma T levels were significantly higher with TU than with T gel at each measuring point (Table 1). Plasma SHBG levels fell significantly over the 9-month study period with T gel, but they rose slightly but significantly with TU.
Over the 9-month study period, the IIEF scores rose significantly with both T gel and TU, but the changes were larger with TU than with T gel. Scores of the AMS dropped significantly with both T gel and TU, but the changes were larger with TU than with T gel. Body weights did not change significantly over the study period in either cohort. The waist circumferences declined significantly over the first 9 months of the study with both T gel and TU; however, they declined slightly but significantly further with TU.
There were parallel declines in plasma total cholesterol, LDL, and triglycerides, whereas plasma HDL showed a parallel rise. The magnitude of these changes was greater with TU than with T gel. With both T gel and TU, the declines in waist circumference were significantly correlated with the falls in plasma total cholesterol and LDL. The declines were not correlated with the changes in triglycerides and were inversely correlated with the rises in plasma HDL.
After 9 months, there was a modest but significant drop in values of
systolic and diastolic blood pressure only with TU. No clear correlations
could be established between changes in the variables and the increases in
plasma T levels over baseline
values.
|
Safety Parameters
Plasma PSA values remained stable over the study period with both T gel and
TU, whereas the scores on the IPSS improved slightly but significantly over 9
months with both T gel and TU, and the changes were not different. Levels of
plasma glucose, hemoglobin A1c, SGOT, SGPT, GT, and bilirubin did not
change (data not shown). Hemoglobin and hematocrit levels rose over the 9
months to a similar degree as both T gel and TU. None of the measured single
values exceeded the upper limits of normal.
|
Discussion |
|---|
|
TopAbstractPatients and MethodsResultsDiscussionReferences |
|---|
Plasma dihydrotestosterone (DHT) levels were not measured in this study. It is known that T gel generates high levels of DHT (up to 300% above baseline [Meikle et al, 2004]). However, TU administration also leads to increases in plasma DHT levels of 200% to 300% (Schubert et al, 2004). Therefore, it is not likely that substantial differences in increases in plasma DHT levels biased the outcome of the study. As the above data indicate, increases in plasma estradiol levels are of similar magnitude with either type of treatment.
The difference in patterns of SHBG levels following treatment with T gel and TU was remarkable. SHBG levels fell during the study period with T gel treatment, whereas treatment with TU produced a small but significant increase in spite of a larger increase in plasma T levels with TU than with T gel. This observation could be interpreted as follows. The fall in SHBG levels with T gel could have been a result of the increase in plasma T levels. Then over the course of treatment symptoms of the metabolic syndrome improved to a larger degree with TU than with T gel, and there probably would have been a reduction in hyperinsulinemia (Vermeulen et al, 1996), leading to a rise in plasma SHBG levels. Plasma SHBG has been proposed to be an indicator of the degree of hyperinsulinism of the metabolic syndrome (Strain et al, 1994; Niskanen et al, 2004).
There were several methodologic shortcomings in this study: there were no control groups, and the subjects were not randomized to receive either T gel or TU. Therefore, the positive results of this study and the observation that plasma levels of T in the mid-normal range of reference values are more efficacious than levels in low-normal range must be interpreted with caution until more appropriate studies have been performed.
In conclusion, it appears that improvements in a number of androgen-related functions is more favorable when plasma T levels are in the mid-normal range of reference values of plasma T levels than in the low range of reference values. This notion is becoming increasingly clear in the literature. The thresholds for androgen action vary for the various androgen-dependent biologic functions, and moreover, these thresholds differ among men (Bhasin et al, 2001; Kelleher et al, 2004; Zitzmann et al, 2006). This study argues for checking plasma T levels during T treatment to see if they reach a certain threshold. This applies particularly for treatment with T gel. In this study in which all men received a dose of 50 mg/day with no dose adaptations, the efficacy of treatment was significantly less than with TU, generating plasma T levels in the mid range of reference values. Therefore, patients treated with T, particularly T gel, should receive modifications of the dose administered if the resulting plasma T levels are low and do not reach the mid-normal range of the reference values.
|
References |
|---|
|
TopAbstractPatients and MethodsResultsDiscussionReferences |
|---|
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N,
Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J,
Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in
healthy young men. Am J Physiol Endocrinol Metab. 2001; 281: E1172
–E1181.
Ford ES. Prevalence of the metabolic syndrome defined by the
International Diabetes Federation among adults in the U.S. Diabetes
Care. 2005;28: 2745
–2749.
Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs. 2004; 64: 1861 –1891.[CrossRef][Medline]
Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L,
DeCarolis E, Zoccoli J, Defoy I. The prevalence of erectile dysfunction in the
primary care setting: importance of risk factors for diabetes and vascular
disease. Arch Intern Med. 2006; 166: 213
–219.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2005; 24: e13 –e18.
Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother. 2005;6: 1751 –1759.[CrossRef][Medline]
Jackson G. The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadism. Eur Urol. 2006;50: 426 –427.[CrossRef][Medline]
Kalme T, Seppala M, Qiao Q, Koistinen R, Nissinen A, Harrela M,
Loukovaara M, Leinonen P, Tuomilehto J. Sex hormone-binding globulin and
insulin-like growth factor-binding protein-1 as indicators of metabolic
syndrome, cardiovascular risk, and mortality in elderly men. J Clin
Endocrinol Metab. 2005;90: 1550
–1556.
Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold
for androgen deficiency symptoms. J Clin Endocrinol
Metab. 2004;89: 3813
–3817.
Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay
JB. Low sex hormone-binding globulin, total testosterone, and symptomatic
androgen deficiency are associated with development of the metabolic syndrome
in nonobese men. J Clin Endocrinol Metab. 2006a; 91: 843
–850.
Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol. 2006b;176: 222 –226.[CrossRef][Medline]
Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP,
Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding
globulin predict the metabolic syndrome and diabetes in middle-aged men.
Diabetes Care. 2004; 27: 1036
–1041.
Meikle AW, Matthias D, Hoffman AR. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. BJU Int. 2004;93: 789 –795.[CrossRef][Medline]
Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf). 2006; 65: 275 –281.[CrossRef][Medline]
Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. 2004; 6: 208 –215.[CrossRef][Medline]
Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel
M, Ernst M, Mellinger U, Krone W, Jockenhovel F. Intramuscular testosterone
undecanoate: pharmacokinetic aspects of a novel testosterone formulation
during long-term treatment of men with hypogonadism. J Clin
Endocrinol Metab. 2004;89: 5429
–5434.
Strain G, Zumoff B, Rosner W, Pi-Sunyer X. The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. J Clin Endocrinol Metab. 1994; 79: 1173 –1176.[Abstract]
Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab. 1996; 81: 1821 –1826.[Abstract]
Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder
PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel
(AndroGel) treatment maintains beneficial effects on sexual function and mood,
lean and fat mass, and bone mineral density in hypogonadal men. J
Clin Endocrinol Metab. 2004; 89: 2085
–2098.
World Health Organization. Guidelines for the Use of Androgens in Men. Geneva, Switzerland: World Health Organization; 1992 .
Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms
and metabolic risks with serum testosterone in older men. J Clin
Endocrinol Metab. 2006;91: 4335
–4343.
This article has been cited by other articles:
|
|
 |
|
  A. M. Traish, F. Saad, R. J. Feeley, and A. Guay The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease J Androl, September 1, 2009; 30(5): 477 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Guay The Emerging Link Between Hypogonadism and Metabolic Syndrome J Androl, July 1, 2009; 30(4): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Traish, A. Guay, R. Feeley, and F. Saad The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome and Erectile Dysfunction J Androl, January 1, 2009; 30(1): 10 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel The Metabolic Syndrome Endocr. Rev., December 1, 2008; 29(7): 777 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kupelian, F. J. Hayes, C. L. Link, R. Rosen, and J. B. McKinlay Inverse Association of Testosterone and the Metabolic Syndrome in Men Is Consistent across Race and Ethnic Groups J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3403 - 3410. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
